Comparative Pharmacology
Head-to-head clinical analysis: ZYMAR versus ZYMAXID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZYMAR versus ZYMAXID.
ZYMAR vs ZYMAXID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ofloxacin is a fluoroquinolone antibacterial that inhibits DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination.
Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, leading to inhibition of DNA replication and transcription.
1 drop instilled into the affected eye(s) every 2 hours while awake on Day 1, then 1 drop 4 times daily on Days 2 through 7.
1 drop of 0.5% ophthalmic solution in the affected eye(s) every 4 to 6 hours while awake for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 4.5 hours in adults, supporting twice-daily dosing for ocular infections.
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function. In renal impairment, half-life may be prolonged up to 8-12 hours, requiring dose adjustment.
Renal excretion of unchanged drug accounts for approximately 70% of an administered dose; biliary/fecal excretion accounts for about 30%.
Primarily renal excretion as unchanged drug (approximately 80-90% of administered dose). Minimal biliary/fecal elimination (<5%).
Category C
Category C
Fluoroquinolone Antibiotic (Ophthalmic)
Fluoroquinolone Antibiotic (Ophthalmic)